Acute Myeloid Leukaemia and Myelodysplastic Syndrome Gene Panels (Pilot - Not Accredited)

 

Please note, programme name to be changed to Myeloid Gene Panels (Pilot - Not Accredited) on 1st April 2022.

 

The programme is primarily aimed at participants using Next Generation Sequencing (NGS) panels to diagnose and prognosticate Acute Myeloid Leukaemia (AML) and Myelodysplastic Syndrome (MDS). One lyophilised sample from an AML or MDS patient (or cell line material) will be issued per trial distribution. Participants will be expected to test the sample with their in-house panels and report any clinically significant intragenic and/or regulatory element changes such as a nucleotide substitution, small insertion, small deletion or small duplication event. Participants will not be requested to report larger changes affecting genome architecture or copy number changes (>50 kb). Instructions for storage, reconstitution and use of the lyophilised samples are included with the distribution. Two send-outs are issued per annum.

 

 

***NEW IN 2022-2023*** Please note, for the financial year 2022-2023, the Acute Myeloid Leukaemia and Myelodysplastic Syndrome Gene Panels (Pilot – Not Accredited) will expand to encompass a broader range of myeloid malignancies (e.g myeloproliferative neoplasms, juvenile myelomonocytic leukaemia, chronic neutrophilic leukaemia, systemic mastocytosis) which will necessitate a name change to Myeloid Gene Panels (Pilot – Not Accredited). The programme will continue to issue two rounds per annum, each featuring an EQA/PT sample (lyophilised patient/cell line material) for analysis. To facilitate a quicker turnaround time for trial report publication, one distribution will focus on summarising the variants detected by participants (including methodological aspects) and the other will additionally provide educational elements related to variant interpretation/classification.

 

Pre issue testing of samples for this programme is subcontracted, although the final decision about sample suitability lies with the EQA provider; no other activities in relation to this EQA programme are subcontracted.

 

To register for this programme, please click here.

Example Acute Myeloid Leukaemia and Myelodysplastic Syndrome Gene Panels (Not Accredited) Report
192002_AML and MDS GP Report example.pdf
Adobe Acrobat document [1.1 MB]
Print Print | Sitemap

Follow Us Online
Facebook Twitter LinkedIn Youtube

Disclaimer

Last updated 15/12/2021 © UK NEQAS for Leucocyte Immunophenotyping not to be reproduced in all or part without permission.

This website uses cookies. For more information please click here.


Please click here for our privacy policy.


The UK NEQAS Organisation is a Company Limited by Guarantee (No.3012351) and a Registered UK Charity (No.1044013).